Skin allograft rejection in mice lacking inducible nitric oxide synthase

Transplantation

Volumn 64, Issue 4, 1997, Pages 589-593

  Casey, John J ^a   Wei, Xiao Qing ^a   Orr, Douglas J ^a   Alastair Gracie, J ^a   Huang, Fang Ping ^a   Bolton, Eleanor M ^a   Liew, Foo Y ^a   Andrew Bradley, J ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME KINETICS; ENZYME MECHANISM; FEMALE; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; ISOANTIGENS; KINETICS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE; SKIN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030929522     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708270-00007     Document Type: Article

References (37)

1. Liew FY. Nitric oxide in infectious and autoimmune diseases: T cell subsets in infectious and autoimmune diseases. Ciba Foundation Symposium. Chichester: Wiley, 1995; 234.
2. Liew FY. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol 1995; 7: 396.
3. Vladutiu AO. Role of nitric oxide in autoimmunity. Clin Immunol 1995; 76: 1.
4. Hibbs JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87.
5. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543.
6. Drapier JC, Hibbs JB. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulphur enzymes in the macrophage effector cells. J Immunol 1988; 140: 2829.
7. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93: 2684.
8. Corbett JA, Mikhael A, Shimizu J, et al. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 1993; 90: 8992.
9. ω-monomethyl-L-arginine. J Exp Med 1994; 179: 651.
10. Cattell V, Smith J, Jansen A, Rivieros-Moreno V, Moncada S. Localization of inducible nitric oxide synthase in acute renal allograft rejection in the rat. Transplantation 1994; 58: 1399.
11. Winlaw DS, Schyvens CG, Smythe GA, et al. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 1995; 60: 77.
12. Worrall NK, Lazenby WD, Misko TP, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181: 63.
13. Stevens RB, Ansite JD, Mills CD, et al. Nitric oxide-mediated early dysfunction of rat and mouse islets after transplantation. Transplantation 1996; 61: 1740.
14. Worrall NK, Chang K, Suau GM, et al. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ Res 1996; 78: 769.
15. Ioannidis I, Hellinger A, Dehmlow C, et al. Evidence for increased nitric oxide production after liver transplantation in humans. Transplantation 1995; 59: 1293.
16. Benvenuti C, Bories PN, Loisance D. Increased serum nitrate concentration in cardiac transplant patients: a marker for acute allograft cellular rejection. Transplantation 1996; 61: 745.
17. Agarwal A, Youngki K, Matas AR, Alam J, Nath KA. Gasgenerating systems in acute renal allograft rejection in the rat. Transplantation 1996; 61: 93.
18. Yang X, Chowdhury N, Cal B. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994; 94: 714.
19. Hoffman RA, Langrehr JM, Billiar TR, Curran RD, Simmons RL. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220.
20. Langrehr JM, Dull KE, Ochoa JB, et al. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 1992; 53: 632.
21. Stojanovic T, Grone HJ, Gieseler RKH, et al. Enhanced renal allograft rejection by inhibitors of nitric oxide synthase: a non-immunologic influence on alloreactivity. Lab Invest 1996; 74: 496.
22. Paul LC, Myllarniemi M, Muzaffar SHB. Nitric oxide synthase inhibition is associated with decreased survival of cardiac allografts in the rat. Transplantation 1996; 62: 1193.
23. Gorczynski RM, Rossi-Bergman B, Sullivan B, Chen Z. Role of reactive nitrogen intermediates in the regulation of allogeneic skin graft survival in mice after portal vein pretransplant transfusion. Transplantation 1995; 60: 707.
24. ω-monomethyl-L-arginine inhibits nitric oxide production in murine cardiac allografts but does not affect graft rejection. Biochim Biophys Acta 1994; 1226: 225.
25. Wei X-Q, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408.
26. Billingham RE, Medawar PB. Technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
27. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312: 548.
28. Suitters AJ, Foulkes R, Opal SM, et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor α chimeric antibodies in experimental septic shock. J Exp Med 1994; 179: 849.
29. Huang F-P, Feng G-J, Lindop G, Stott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med 1996; 183: 1447.
30. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109.
31. Imagawa DK, Millis JM, Seu P, et al. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation 1991; 51: 57.
32. Hoffman RA, Langrehr JM, Dull KE, McCarthy SA, Jordan ML, Simmons RL. Macrophage synthesis of nitric oxide in the mouse mixed leukocyte reaction. Transplant Immunol 1994; 2: 313.
33. Fu Y, Blankenhorn EP. Nitric oxide-induced anti-mitogenic effects in high and low responder strains. J Immunol 1992; 144: 2217.
34. Mill CD. Molecular basis of "suppressor" macrophages: arginine metabolism via the nitric oxide synthase pathway. J Immunol 1991; 146: 2719.
35. Gregory SH, Saghimeni AJ, Wing EJ. Arginine analogues suppress antigen-specific and -nonspecific T lymphocyte proliferation. Cell Immunol 1994; 153: 527.
36. Beckman JS, Backman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl production by peroxynitrile: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620.
37. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995; 92: 457.